secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001558370-24-004166
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroBo reports FY 2023 net loss $12.5M; cash $22.4M; DA-1726 Phase 1 to dose Q2 2024
--------------------------------------------------------------------------------

- Net loss $12.5M ($2.46 per share) vs $14.0M in FY 2022; R&D spend rose to $9.2M.
- Cash $22.4M as of Dec. 31, 2023, expected to fund operations into Q4 2024.
- DA-1726 Phase 1 obesity trial: first site IRB approved; first patient dosing expected Q2 2024.
- DA-1241 Phase 2a MASH trial: SRC approval to continue; full data expected H2 2024.
- Marshall Woodworth appointed permanent CFO; company regained Nasdaq compliance after reverse split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024004166/0001558370-24-004166-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024004166/nrbo-20240328x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-004166

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer